Evoke Pharma (NASDAQ:EVOK) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research report report published on Sunday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Performance

Shares of NASDAQ EVOK opened at $5.13 on Friday. The company has a market cap of $7.64 million, a PE ratio of -0.47 and a beta of 0.16. Evoke Pharma has a 52-week low of $3.54 and a 52-week high of $12.32. The firm’s 50 day moving average price is $4.63 and its 200-day moving average price is $4.82.

Institutional Trading of Evoke Pharma

An institutional investor recently bought a new position in Evoke Pharma stock. Corsair Capital Management L.P. purchased a new stake in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned about 1.42% of Evoke Pharma as of its most recent filing with the Securities & Exchange Commission.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.